Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568479 | 0.88 | NAMPT (0.66) | NAMPTCYP17A1MKNK1MKNK2CYP3A4 | |
| SCHEMBL9439389 | 0.86 | CYP3A4 (0.59) | NAMPTCYP3A4RAB9ALMNA | |
| SCHEMBL6447258 | 0.86 | HDAC1 (0.52) | CYP17A1RAB9ALMNA | |
| SCHEMBL5749 | 0.82 | CYP17A1 (0.44) | NAMPTCYP17A1CYP3A4RAB9AWNT3A | |
| SCHEMBL3491473 | 0.81 | CYP17A1 (0.61) | NAMPTCYP17A1WNT3A | |
| SCHEMBL23291114 | 0.81 | IDO1 (0.55) | NAMPTCYP17A1MKNK1MKNK2CYP3A4 | |
| SCHEMBL17963188 | 0.80 | CYP17A1 (0.53) | NAMPTCYP17A1CYP3A4RAB9ALMNA | |
| SCHEMBL3490176 | 0.79 | KDM4D (0.48) | NAMPTCYP17A1MKNK1MKNK2NAAA | |
| SCHEMBL11966094 | 0.79 | KDM4D (0.48) | NAMPTCYP17A1MKNK1MKNK2NAAA | |
| SCHEMBL6164499 | 0.78 | NAMPT (0.67) | NAMPTCYP17A1MKNK1MKNK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1310905-C | Antivirally active heterocyclic azahexane derivatives | NOVARTIS AG (CH) | 2007-04-18 | — | — | CN | disclosed |
| CN-1616453-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS AG (CH) | 2005-05-18 | — | — | CN | disclosed |
| CN-1193010-C | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2005-03-16 | — | — | CN | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| CN-1082508-C | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2002-04-10 | — | — | CN | disclosed |
| CN-1319587-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2001-10-31 | — | — | CN | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| CN-1216539-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 1999-05-12 | — | — | CN | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |